Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells

Sherlock JP. et al, (2017), Nature Medicine, 18, 1069 - 76

Spondyloarthropathy: interleukin 23 and disease modification

Sherlock J. et al, (2017), The Lancet, 385, 2017 - 2018

The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases.

Sherlock J. et al, (2017), Current Opinion in Rheumatology, 27, 71 - 75

The critical role of interleukin-23 in spondyloarthropathy

Sherlock J. et al, (2017), Molecular immunology, 57, 38 - 43

What can rheumatologists learn from translational cancer therapy?

Sherlock JP. et al, (2017), Arthritis Research & Therapy, 15

The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases

Sherlock JP. et al, (2015), Current Opinion in Rheumatology, 27, 71 - 75

IL-23 in health and disease

Sherlock JP. et al, (2014), Cytokine Frontiers: Regulation of Immune Responses in Health and Disease, 179 - 198

The critical role of interleukin-23 in spondyloarthropathy.

Sherlock JP. et al, (2014), Mol Immunol, 57, 38 - 43

Interleukin-23: a promising therapeutic target in seronegative spondyloarthropathy.

Sherlock JP. and Cua DJ., (2013), Curr Opin Pharmacol, 13, 445 - 448

Interleukin 23 is critical in the pathogenesis of spondyloarthropathy and acts on a novel population of interleukin 23R+entheseal resident cells

Sherlock JP. et al, (2013), LANCET, 381, 14 - 14

Include forthcoming?